Answers are grounded in this paper and cite their sources.
The BRCA1-associated protein 1 (BAP1) gene mutation defines a subtype of aggressive clear cell renal cell carcinoma (ccRCC) with distinct molecular phenotypes and poor prognosis. In-depth analysis of its regulatory role as a key tumor suppressor in multi-dimensional biological processes may help lay the groundwork for future precision treatment strategies, although their clinical implementation remains investigational. This review systematically summarizes the core functions of BAP1 in epigenetic regulation, DNA damage repair, remodeling of the immune microenvironment, and metabolic reprogramming. It also focuses on explaining the specific therapeutic vulnerabilities induced by BAP1 deficiency, including the synthetic lethal effect mediated by PARP inhibitors, the sensitivity of epigenetic targets such as EZH2/HDAC, and the synergistic mechanism of immune checkpoint inhibitors. The literature search was conducted based on the PubMed/Medline database, using keywords such as “BAP1”, “ccRCC”, “synthetic lethality”, “immunotherapy” for systematic screening and integrated analysis. BAP1-mutant ccRCC has become an important paradigm in precision oncology research. Currently, single-agent targeted or immunotherapy has shown initial efficacy, but the problem of drug resistance is prominent. Future therapeutic advances will depend on rationally designed combination regimens; whether biomarker-guided patient stratification can inform such regimens awaits prospective clinical validation.
No takes yet. Share an insight, caveat, or question.
Gong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: